In conclusion, this study successfully established a preoperative, noninvasive predictive model that integrates CD133‐positive CTCs with key clinical characteristics to assess the pathological high‐risk factors in patients with NSCLC. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.